Bladder cancer represents a significant health burden worldwide, with non-muscle-invasive tumours representing the majority of new bladder cancer diagnoses. Non-muscle-invasive bladder cancer (NMIBC) has a high prevalence and forms a large proportion of the caseload in urological practice, accounting for a significant cost in terms of urological healthcare. The last two decades have seen the development and refinement of guidelines from national and international organisations aiming to optimise management of NMIBC and bladder cancer in general. This review outlines the most recent European and United Kingdom guidelines on NMIBC, and in particular focuses on comparing and contrasting key recommendations from guidelines published by the European Association of Urology and the UK-based National Institute for Clinical Excellence.
Level of evidence: Not applicable for this multicentre audit.
van der MeijdenAOosterlinckWBrausiMet al. Significance of bladder biopsies in Ta,T1 bladder tumors: A report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol1999; 35: 267–271.
9.
HaraTTakahashiMGondoTet al. Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: Retrospective analysis of 173 Japanese cases. Int J Urol2009; 16: 293–298.
10.
AbernMROwusuRAAndersonMRet al. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: A systematic review and meta-analysis. J Natl Compr Canc Netw2013; 11: 477–484.
11.
SylvesterRJOosterlinckWvan der MeijdenAP.A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol2004; 171 (6Pt 1): 2186–2190, quiz 2435.
12.
PerlisNZlottaARBeyeneJet al. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: An updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol2013; 64: 421–430.
13.
BrausiMColletteLKurthKet al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies. Eur Urol2002; 41: 523–531.
14.
GrimmMOSteinhoffCSimonXet al. Effect of routine repeat transurethral resection for superficial bladder cancer: A long-term observational study. J Urol2003; 170: 433–437.
15.
DivrikRTYildirimUZorluFet al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: A prospective, randomized clinical trial. J Urol2006; 175: 1641–1644.
16.
DivrikTYildirimUEroğluASet al. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?J Urol2006; 175: 1258–1261.
17.
SylvesterRJvan der MeijdenAPOosterlinckWet al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol2006; 49: 466–465; discussion 475–477.
18.
Fernandez-GomezJMaderoRSolsonaEet al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: The CUETO scoring model. J Urol2009; 182: 2195–2203.
19.
HolmangSAndiusPHedelinHet al. Stage progression in Ta papillary urothelial tumors: Relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol2001; 165: 1124–1128; discussion 1128–1130.
20.
BorhanAReederJEO’ConnellMJet al. Grade progression and regression in recurrent urothelial cancer. J Urol2003; 169: 2106–2109.
21.
GofritONPodeDLazarAet al. Watchful waiting policy in recurrent Ta G1 bladder tumors. Eur Urol2006; 49: 303–306; discussion 306–307.
MariappanPSmithG. A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J Urol2005; 173: 1108–1111.
